Cessatech A/S Announces Financial Results for the Full Year 2025

Full year 2025 for the period 1 January - 31 December (Q4'2025 results in brackets):

• Net revenue: KDKK 5,718 (1,989)
• Operating result: KDKK -14,967 (-1,836)
• Net result: KDKK -10,904 (-773)
• Cash at bank end of the period: KDKK 8,591 (8,591)
• Earnings per share*: KDKK -0.60 (-0.04)
• Solidity**: 91% (91%)

'**Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 December 2025 amounted to 18,576,437 shares, the average number of shares during the full year was 18,090,665 **Solidity: Total equity divided by total capital and liability.

The Annual Report is presented for approval at the Annual General Meeting, to be held on 28 March 2026. The Board of Directors and the CEO propose that no dividend be paid for the financial year from 1 January 2025 to 31 December 2025.

The Annual Report 2025 is available on Cessatech's website.

Highlights during the full year 2025

• Announced positive top-line results from Study 0202, the final required paediatric clinical study for CT001, confirming its safety and efficacy profile and enabling initiation of the European regulatory submission process.
• Received a positive Notified Body opinion under the EU Medical Device Regulation (MDR) for CT001, confirming that the device component meets applicable EU safety and performance requirements.
• Submitted a Paediatric Use Marketing Authorisation (PUMA) application for CT001 to the European Medicines Agency (EMA), which was subsequently validated.
• Advanced U.S. activities through an extended collaboration with STAQ Pharma and completed technology transfer activities supporting near-term hospital supply.
• Strengthened the company's financial position through a directed share issue raising approximately DKK 15 million.
• Enhanced Executive Management with the appointment of Martin Juhl as Chief Scientific Officer (CSO).